Dapagliflozin Therapy In Cardiac Surgery

This randomized controlled trial is to assess the effects of perioperative dapagliflozin on type 2 diabetic patients undergoing cardiac surgery

Inclusion Criteria:Age ≥ 18 years at screeningScheduled for cardiac surgeryDiagnosis of Type 2 DiabetesProvision of signed informed consent prior to any study specific proceduresExclusion Criteria:Emergency surgery and non-primary surgeryModerate and severe dehydration; systolic pressure≤90mmHg; unstable haemodynamicsHistory of diabetic ketoacidosis; type 1 diabetes mellitusReceiving therapy with an SGLT2 inhibitor within 4 weeks prior to enrolmentKnown allergy or hypersensitivity to dapagliflozin or other SGLT-2 inhibitorsEstimated glomerular filtration rate (eGFR) <30 mL/min/1.73 m2 or requiring dialysis; unstable or rapidly progressing renal disease at the time of randomisationSerious hepatic diseaseWomen who are pregnant, nursing, or who plan to become pregnant while in the trialCurrently enrolled in another investigational drug study, or less than 30 days